Menu Menu Menu Menu
To Top

Search By Topic

Formulation

44 Articles available
Continuous Manufacturing

Innovation and Formulation

Thomas Hofmaier, Head of Business Unit Process Technology Pharma, Glatt Air Techniques

PTV-M03-17-IN-005
CDMO

Topical Drug Formulations – Strong Growth Based on New Understandings: Q&A with BASF Pharma Solutions

PAO-M04-17-NI-014
Excipients

Making it Simple

Ken Seufert, Managing Director, Meggle USA

PTV-M11-16-AP-030
Formulation

Focusing on Patient Compliance

Brian Wilson, Technical Development Manager, SPI Pharma

PTV-M01-17-NS-011
Formulation

Partnering for Formulation Development

Elsie Melsopp, Director of Formulation, Alcami

PTV-M11-16-AP-001
Formulation

Innovative Drug Delivery Technology

Kevin Haehl, General Manager, North America, Unither Pharmaceuticals

PTV-M11-16-AP-006
CDMO

Choosing the Right Pathway

Ken Phelps, President & CEO, Camargo

PTV-M11-16-AP-007
CDMO

Servier Offers Quality Service

Gwenael Servant, Managing Director, Servier CDMO

PTV-M11-16-AP-012
Formulation

Enhancement and Availability

Edward Rudnic, CEO, Dispersol

PTV-M11-16-AP-015
Equipment

Freund Vector Can’t Go Wrong with Granurex

Shawn Engels, Senior Process Development Engineer, Freund Vector

PTV-M11-16-AP-017
Formulation

Expanding Capabilities

Frank Sorce, Vice President of Business Development, UPM Pharmaceuticals

PTV-M11-16-AP-023
CDMO

Understanding Solid State Properties for Formulation Success

PAO-M04-17-NI-001
API

Energizing Client Portfolios with Patient-Friendly Dosage Forms

PAP-Q1-17-CL-001
Excipients

Spending on Excipients Grows & Diversifies

PAP-Q1-17-FA-004
CDMO

Operational Excellence in Outsourced Fill-Finish Services

PAP-Q1-17-IC-001
API

Expanding the Commercial Options for Preparation of Amorphous Solid Dispersions

PAP-Q1-17-CL-006
API

Particle Engineering for Improved Bioavailability in Oral Solid Dose Medications

PAP-Q1-17-CL-014
API

Next-Generation OSD Manufacturing Strategy

PAP-Q1-17-CL-015
CDMO

Enhancing Responsiveness with Embedded Flexibility

PAP-Q1-17-CL-008
Equipment

An OEE Approach To Solid Dose Equipment Purchasing and Implementation

PAP-Q1-17-CL-005
Formulation

Pharmapack 2017: Innovations in Medical Devices

PAO-M02-17-NI-001
Excipients

What’s New at AAPS: Materials

PAP-M11-16-NI-001
API

Two Promising Small-Molecule Orphan Drugs in Clinical Trials

PAP-Q04-16-TT-001
API

A New Industry Think Tank Forum for Leaders of Outsourced Services and Customers

PAP-Q04-16-NS-001
API

Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services

PAP-Q04-16-CL-004
Formulation

Better Design, Better Outcomes, Better Economics

PAP-Q04-16-IL-001
API

Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability

PAP-Q04-16-CL-006
API

Future Pharma Partner Models: Pharma 3.0

PAP-Q03-16-FA-001
API

Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience

PAP-Q03-16-CL-005
API

Accelerating Approval and Reducing Costs of Spray Dried Drugs Through Development by Design (DbD)

PAP-Q03-16-CL-011
API

Biocatalysis Versus Chemocatalysis

MCP-M04-16-NI-001
CDMO

From Qualified to Ideal: The Importance of Partnership

PAP-Q02-16-VP-001
Excipients

Optimising Excipients to Improve Bioavailability

MCP-M03-16-NI-001
API

Formulation Challenges Drive Interest in CDMOS

MCP-M01-16-NI-001
API

In-depth Process and Product Expertise – This is Key to CDMO Support of Orphan Drug and Breakthrough Therapy Development & Commercialization

PAP-Q4-15-CL-004
Formulation

Choosing the Optimal Drug Delivery System to Meet Patient Needs

PAP-Q4-15-CL-008
Outsourcing

CRO or CMO: Which Is Best For Your Preformulation Needs?

LSL-M05-15-NI-001
Excipients

Speaking the Same Language – The Gap Between the Sales Pitch and Supplier Selection Criteria – And How It Applies in the Excipients Market

APR-M03-15-NI-004
Equipment

Trends In Outsourcing – The Benefit Of Engaging A CMO For Injectable Product Development Through To Fill Finish

MCP-M03-15-NI-002
CDMO

New Technologies In Fill-Finish May Bring Brand Loyalty Along with Improved Patient Safety

LSL-M04-14-NI-001
Outsourcing

Trends In Outsourcing — What’s Going On In Big Pharma

LSL-M06-13-NI-001
Formulation

Outsourcing and the Oral Solid Dose: Will Challenges Lead to New Patterns of Outsourcing?

CIO-M06-13-NI-001
Outsourcing

The Right Preformulation / Formulation Outsourcing Partner Can Alleviate Challenges To Reducing Costs

CIO-M09-12-NI-001
CDMO

Customer Drivers Influencing Supplier Differentiation

PTO-M08-11-NI-001
//Fix for text overflow in cards